Skip to main content
. 2021 Nov 3;12:6340. doi: 10.1038/s41467-021-26570-8

Fig. 2. In vivo screening identifies genomically associated radiosensitization in CREBBP/EP300-mutated tumors.

Fig. 2

a Ratio of CREBBP mutant vs. wild type for target fold change (y axis) and RSA log p-value (x axis) for radiosensitizing targets selected from Fig. 1. b, c Difference between CREBBP/EP300 mutant (n = 3) and wild-type (n = 2) tumors from the in vivo shRNA study as a function of target fold change (c) and RSA log p-value (c). (*)—two-sided p < 0.05 versus wild type. d Clonogenic assays following irradiation of HNSCC cell lines expressing control and either CREBBP or EP300 shRNA using a minimum of 3 independent samples for each condition and are presented as mean values +/−SEM. In B–D, comparisons were evaluated using ANOVA with post hoc analysis adjusted for multiple comparisons. For (*) shCREBBP-2 and (#) shCREBBP-3, p < 0.05 versus control. All p-values two-sided.